Organisations › Biological

SIGA Technologies

New York, NY, United StatesFounded 1995Industry

SIGA Technologies develops and supplies a smallpox antiviral treatment for government stockpiles. CBRNE-relevant work is a notable product line according to its website. It is headquartered in New York, NY, United States.

What it does

antiviralssmallpox antiviralTPOXX

Threats covered

smallpox/orthopoxviruses
Categories

Profile

SIGA Technologies is a New York-based pharmaceutical company, incorporated in 1995 and listed on Nasdaq under SIGA, that sells TPOXX (tecovirimat) to the US and international governments. Its BARDA contract 19C was completed after final intravenous TPOXX deliveries in the second quarter of 2026, and the company said it is pursuing a new multi-year Strategic National Stockpile procurement contract, with the request for proposals delayed by changes at the Department of Health and Human Services.

More profile

In 2025 BARDA added 27 million dollars for manufacturing and paediatric TPOXX development. The company's results for 2025 and its second quarter 2026 report are public.

Ownership

Publicly listed on Nasdaq (SIGA)

Parent: none (publicly listed) (checked)

Sources (5)
Not verified or not found
  • Contract value of the completed 19C contract: not read.
  • Timing of the new procurement award: not known.
Questions

What does SIGA Technologies do?

SIGA Technologies develops and supplies a smallpox antiviral treatment for government stockpiles. CBRNE-relevant work is a notable product line according to its website.

Where is SIGA Technologies based?

HQ (as found): New York, NY. HQ country: US.

Who owns SIGA Technologies?

Publicly listed on Nasdaq (SIGA). Parent: none (publicly listed) (checked)

Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction